Loading clinical trials...
Loading clinical trials...
A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 as Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory Acute Myeloid Leukaemia Patients Not Eligible for Intensive Induction Therapy.
Conditions
Interventions
AZD2811
Azacitidine
+1 more
Locations
11
United States
Research Site
Denver, Colorado, United States
Research Site
Sarasota, Florida, United States
Research Site
Detroit, Michigan, United States
Research Site
Charlotte, North Carolina, United States
Research Site
Canton, Ohio, United States
Research Site
Oklahoma City, Oklahoma, United States
Start Date
July 31, 2017
Primary Completion Date
March 25, 2021
Completion Date
March 25, 2021
Last Updated
April 5, 2022
NCT07148180
NCT05534620
NCT06345365
NCT06326697
NCT06790680
NCT01497002
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions